###begin article-title 0
###xml 74 79 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Biochemical and virological analysis of the 18-residue C-terminal tail of HIV-1 integrase
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 112 117 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 239 244 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 412 417 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 465 470 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 492 497 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The 18 residue tail abutting the SH3 fold that comprises the heart of the C-terminal domain is the only part of HIV-1 integrase yet to be visualized by structural biology. To ascertain the role of the tail region in integrase function and HIV-1 replication, a set of deletion mutants that successively lacked three amino acids was constructed and analyzed in a variety of biochemical and virus infection assays. HIV-1/2 chimers, which harbored the analogous 23-mer HIV-2 tail in place of the HIV-1 sequence, were also studied. Because integrase mutations can affect steps in the replication cycle other than integration, defective mutant viruses were tested for integrase protein content and reverse transcription in addition to integration. The F185K core domain mutation, which increases integrase protein solubility, was furthermore analyzed in a subset of mutants.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 278 287 278 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 352 358 352 358 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-276 </sub>
###xml 367 372 367 372 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-273</sub>
###xml 509 515 509 515 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-270 </sub>
###xml 112 117 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 347 350 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 362 365 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 504 507 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 523 528 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Purified proteins were assessed for in vitro levels of 3' processing and DNA strand transfer activities whereas HIV-1 infectivity was measured using luciferase reporter viruses. Deletions lacking up to 9 amino acids (1-285, 1-282, and 1-279) displayed near wild-type activities in vitro and during infection. Further deletion yielded two viruses, HIV-11-276 and HIV-11-273, that displayed approximately two and 5-fold infectivity defects, respectively, due to reduced integrase function. Deletion mutant HIV-11-270 and the HIV-1/2 chimera were non-infectious and displayed approximately 3 to 4-fold reverse transcription in addition to severe integration defects. Removal of four additional residues, which encompassed the C-terminal beta strand of the SH3 fold, further compromised integrase incorporation into virions and reverse transcription.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 5 10 5 10 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-270</sub>
###xml 17 22 17 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-266</sub>
###xml 342 351 342 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 12 15 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 32 37 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-11-270, HIV-11-266, and the HIV-1/2 chimera were typed as class II mutant viruses due to their pleiotropic replication defects. We speculate that residues 271-273 might play a role in mediating the known integrase-reverse transcriptase interaction, as their removal unveiled a reverse transcription defect. The F185K mutation reduced the in vitro activities of 1-279 and 1-276 integrases by about 25%. Mutant proteins 1-279/F185K and 1-276/F185K are therefore highlighted as potential structural biology candidates, whereas further deleted tail variants (1-273/F185K or 1-270/F185K) are less desirable due to marginal or undetectable levels of integrase function.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 566 567 566 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 513 518 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Retrovirus replication proceeds through a series of steps that initiate upon virus entry into a cell, followed by particle uncoating and reverse transcription. To support productive replication, the resulting double stranded cDNA must be integrated into a cell chromosome. The integrated DNA provides an efficient transcriptional template for viral gene expression and ensures for segregation of viral genetic material to daughter cells during division. Due to its essential nature, the integrase (IN) encoded by HIV-1 is an intensely studied antiviral drug target [1].
###end p 9
###begin p 10
###xml 168 171 168 171 <sub xmlns:xlink="http://www.w3.org/1999/xlink">OH </sub>
###xml 292 293 292 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 294 295 294 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 496 497 496 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 618 619 618 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 620 621 620 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 765 768 765 768 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 773 776 773 776 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 786 787 786 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 788 790 788 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 221 226 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 624 629 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Integration can be divided into three enzyme-based steps, the first two of which are catalyzed by IN. In the initial 3' processing reaction, IN removes the terminal pGTOH dinucleotides from the 3' ends of the blunt-ended HIV-1 reverse transcript, yielding the precursor ends for integration [2-4]. In the second step, DNA strand transfer, IN uses the 3'-oxygens to cut the chromosomal target DNA in a staggered fashion and at the same time joins the viral 3' ends to the resulting 5' phosphates [3]. The final step, repair of single stranded gaps and joining of viral DNA 5' ends, is accomplished by cellular enzymes [5,6]. HIV-1 IN activities can be measured in vitro using oligonucleotide DNA substrates that mimic the ends of the reverse transcript and either Mg2+ or Mn2+ cofactor [7-10].
###end p 10
###begin p 11
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 450 452 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 453 455 453 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 506 508 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 529 531 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 532 534 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 553 555 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 658 660 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 693 695 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 715 717 715 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 718 720 718 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 768 770 768 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 71 76 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 408 413 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
IN is a multi-domain protein consisting of the N-terminal domain (NTD, HIV-1 residues 1-49), catalytic core domain (CCD, residues 50-212), and C-terminal domain (CTD, residues 213-288). The NTD contains a conserved HHCC Zn-coordination motif, and Zn-binding contributes to IN multimerization and catalytic function [11,12]. The CCD contains an invariant triad of acidic residues (Asp-64, Asp-116, Glu-152 of HIV-1) that forms the enzyme active site [13-16]. The CCD also contributes to IN multimerization [17] and engages viral [18-20] and chromosomal [21,22] DNAs during integration. The CTD, which is the least conserved of the domains among retroviruses [23], also contributes to specific [24] and non-specific [25-27] DNA interactions, as well as multimerization [28].
###end p 11
###begin p 12
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 485 487 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 488 490 488 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 583 585 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 662 664 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 665 667 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 697 699 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 707 709 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 736 738 733 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1123 1125 1120 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 30 35 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 368 373 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 375 380 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 391 402 <span type="species:ncbi:11741">visna virus</span>
###xml 690 695 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 702 705 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
###xml 716 734 <span type="species:ncbi:11886">Rous sarcoma virus</span>
###xml 1028 1033 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Insight into the mechanism of HIV-1 integration is somewhat hampered by lack of relevant 3-dimensional information, as structures for the enzyme bound to its DNA substrates, or the free holoenzyme, have yet to be reported. NTD-CCD [29-31] and CCD-CTD [32-34] two-domain x-ray crystal structures have nevertheless been informative. Three NTD-CCD structures, containing HIV-1, HIV-2, or maedi-visna virus domains, have revealed a dimer-of-dimers architecture for the active IN tetramer [29,30] and the high affinity binding mode of the common lentiviral integration cofactor LEDGFp75 [31]. An SH3 fold comprised of five beta strands makes up the heart of the CTD [35,36], and a comparison of HIV-1 [32], SIV [33], and Rous sarcoma virus [34] CCD-CTD structures reveals considerable flexibility in CTD positioning with respect to the different CCDs. Nevertheless, extended viral DNA binding surfaces were ascribed to each CCD-CTD structure. Although residues 271-288, herein referred to as the tail, were present in the two-domain HIV-1 construct, they were disordered and therefore unseen in the resulting crystal structure [32].
###end p 12
###begin p 13
###xml 100 106 100 106 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-270 </sub>
###xml 180 182 180 182 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 271 277 271 277 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-279 </sub>
###xml 318 320 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 498 500 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1134 1136 1134 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 52 57 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 323 328 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 567 572 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 741 746 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 781 786 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The roles of the C-terminal tail in IN function and HIV-1 replication are largely unexplored. The IN1-270 deletion mutant that lacked the tail supported 10-50% of wild-type (WT) Mn2+-dependent 3' processing and DNA strand transfer activities, whereas the activities of IN1-279 were largely unimpaired (50-100% of WT) [25]. HIV-1 carrying the substitution of Ala for Lys-273 grew like the WT in Jurkat T cells, dispensing an obvious role for this highly conserved tail residue in virus replication [37]. To learn more about the role of this region in IN catalysis and HIV-1 replication, successive three amino acid deletion mutants were constructed and analyzed in various enzymatic and virus infection assays. The somewhat larger 23-residue HIV-2 tail was moreover swapped for the HIV-1 sequence to assess the activities of tail chimera enzyme and virus., C-terminal deletion mutants that lack all or part of the tail could be useful structural biology candidates due to their inability to adopt an ordered fold in previous crystal structures. Thus, one goal of this study was to evaluate the solubility-enhancing F185K CCD mutation [38] for its potential effects on the in vitro activities of tail deletion mutant enzymes.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
Plasmid DNA constructions
###end title 15
###begin p 16
###xml 40 42 40 42 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 82 84 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 156 159 156 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vif</italic>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 978 979 978 979 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 1065 1066 1065 1066 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 1303 1309 1303 1309 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CTCGAG</underline>
###xml 1386 1392 1386 1392 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CTTAAG</underline>
###xml 1631 1636 1631 1636 <sub xmlns:xlink="http://www.w3.org/1999/xlink">NL4-3</sub>
###xml 1664 1666 1664 1666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 777 782 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 908 913 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1626 1629 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Bacterial expression vector pKBIN6Hthr [39] and viral IN shuttle vector pUCWTpol [40] were previously described. Because the IN tail overlaps the 5' end of vif, shuttle vector pUCWTpol3stop, which harbored three stop codons after Vif residue Asn-19, was constructed by PCR using Pfu Ultra DNA polymerase (Stratagene, La Jolla, CA) and primers AE1064 (5'-ACAGGATGAGGATTAACTGATGATAAGCTTTAGTAAAACACCATATG)/AE1065 (5'-CATATGGTGTTTTACTAAAGCTTATCATCAGTTAATCCTCATCCTGTC). IN deletion mutations were subsequently constructed in pUCWTpol3stop or pKBIN6Hthr by PCR. Plasmid pUCWTpolBam-Spe, which contains unique BamHI and SpeI sites downstream of the IN coding region and a stop codon after Arg-17 in Vif [41], was used to swap tail sequences as follows. AAA/CAG/ATG, which encodes for HIV-1 residues Lys-273, Gln-274, and Met-275, was changed to GGT/CGA/CTG to imbed a unique SalI site in pUCWTpolSal-Bam-Spe at the HIV-1/2 tail boundary. A linker constructed by annealing AE3697 (5'-PO4-TCGACAGGAGATGGACAGCGGAAGTCACCTGGAGGGCGCAAGAGAGGACGGTGAGATGGCATAAG) with AE3698 (5'-PO4-GATCCTTATGCCATCTCACCGTCCTCTCTTGCGCCCTCCAGGTGACTTCCGCTGTCCATCTCCTG) was then ligated to SalI/BamHI-digested pUCWTpolSal-Bam-Spe. To move the chimera tail to pKBIN6Hthr, pUCWTpolSal-Bam-Spe was amplified using XhoI-tagged AE3699 (5'-TGGTGCTCGAGTGCGGACCCACGCGGGACGAGTGCCATCTCACCGTCCTCTCTTGC) and AflII-tagged AE3700 (AACATCTTAAGACAGCAGTAC) and the resulting digested fragment was ligated with XhoI/AflII-cut pKBIN6Hthr. Mutated AgeI-PflMI 1.8 kb fragments from pUCWTpol3stop or pUCWTpolSal-Bam-Spe were swapped for the corresponding fragment in the single round HIV-1NL4-3-based vector pNLX.Luc(R-) [42]. All plasmid regions constructed by PCR were analyzed by DNA sequencing to verify targeted changes and lack of unwanted secondary mutations.
###end p 16
###begin title 17
Protein expression and purification
###end title 17
###begin p 18
###xml 0 17 0 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli </italic>
###xml 29 31 29 31 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 219 223 206 210 <sub xmlns:xlink="http://www.w3.org/1999/xlink">600 </sub>
###xml 692 693 670 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 780 782 758 760 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1016 1018 988 990 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 1798 1800 1770 1772 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 0 16 <span type="species:ncbi:562">Escherichia coli</span>
Escherichia coli strain PC2 [43] transformed with IN expression constructs were grown for 16 h at 30degreesC. The next day bacteria subcultured at 1:30 in 600 ml LB-100 mug/ml ampicillin were grown at 30degreesC until A600 of 0.6, at which time expression was induced by the addition of 0.6 mM isopropyl-beta-D-thiogalactopyranoside. Cells were harvested following 5 h of induction at 28degreesC. The bacterial pellet resuspended in ice-cold buffer A [25 mM Tris-HCl, pH 7.4, 1 M NaCl, 7.5 mM 3-[(3-Cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonate (CHAPS)] containing 25 mM imidazole-0.5 mM phenylmethanesulphonylfluoride was sonicated. After centrifugation for 30 min at 39,000 g, the supernatant was incubated with 0.6 ml of buffer A-25 mM imidazole-equilibrated Ni2+-nitrilotriacetic acid (Ni-NTA) agarose beads (QIAGEN, Valencia, CA) at 4degreesC for 3 h. The beads were washed twice with 20 volumes of buffer A-25 mM imidazole followed by washing with 30 volumes of buffer A-35 mM imidazole. IN-His6 was eluted with buffer A-200 mM imidazole. IN containing fractions identified by Na dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis were pooled and dialyzed overnight against buffer D [25 mM Tris-HCl, pH 7.4, 1 M NaCl, 7.5 mM CHAPS, 10% glycerol (w/v), 10 mM dithiothreitol (DTT)]. The His-Tag was removed using 40 U of thrombin (Sigma-Aldrich, St. Louis, MO) per mg of protein for 3 h at room temperature, which left the heterologous LVPR sequence at each C-terminus. After removal of thrombin by incubation with Benzamidine beads (Novagen, Madison, WI), IN was concentrated using Centricon-10 Concentrators (Millipore, Billerica, MA) and dialyzed against buffer D for 4 h. Protein concentration was determined by spectrophotometer, and aliquots flash frozen in liquid N2 were stored at -80degreesC. Quantitative image analysis (Alpha Innotech FlourChem FC2, San Leandro, CA) of Coomassie-stained gels revealed that each IN preparation was minimally 90% pure.
###end p 18
###begin p 19
###xml 81 83 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
Recombinant LEDGFp75 expressed in bacteria was purified as previously described [44]. LEDGFp75 concentrations were determined using the Bio-Rad protein assay kit (Hercules, CA). Exonuclease III was from New England Biolabs (Beverley, MA).
###end p 19
###begin p 20
###xml 33 35 33 35 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
Anti-IN monoclonal antibody 8G4 [45] was purified from hybridoma cell supernatant using protein G sepharose (GE Healthcare, Piscataway, NJ) following the manufacturer's recommendations. 500 ml of cell supernatant loaded onto 1 ml of protein G beads were subsequently washed with phosphate-buffered saline. Antibody eluted with 20 mM glycine-HCl, pH 2.8 was immediately neutralized by addition of 1 M Tris-HCl, pH 8.5. Pooled fractions were concentrated by ultrafiltration, and resulting antibody concentration was determined by spectrophotometry.
###end p 20
###begin title 21
In vitro integration assays
###end title 21
###begin p 22
###xml 227 229 223 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 380 383 376 379 <sub xmlns:xlink="http://www.w3.org/1999/xlink">OH </sub>
###xml 434 435 430 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 436 438 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 572 574 564 566 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 656 658 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 32 37 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Oligonucleotides that mimic the HIV-1 U5 end were used as viral DNA substrates. AE143 (5'-ACTGCTAGAGATTTTCCACACTGACTAAAA) and AE191 (5'-TTTTAGTCAGTGTGGAAAATCTCTAGCAG) were annealed prior to filling-in the 3' recess with [alpha-32P]TTP (3000 Ci/mmol; PerkinElmer, Waltham, MA) using Sequenase version 2.0 T7 DNA polymerase (GE Healthcare) to label the phosphodiester within the pGTOH dinucleotide that is cleaved during 3' processing [3,46]. To prepare a 30 bp preprocessed duplex for DNA strand transfer, AE155 (5'-TTTTAGTCAGTGTGGAAAATCTCTAGCA) 5'-end labeled with [gamma-32P]ATP (3000 Ci/mmol; PerkinElmer) using T4 polynucleotide kinase (GE Healthcare) [46] was annealed with AE143. Unincorporated radionuclide was removed by passing labeled duplexes through Bio-Spin 6 columns (Bio-Rad) equilibrated with 10 mM Tris-HCl, pH 8.0-20 mM NaCl-0.1 mM EDTA.
###end p 22
###begin p 23
###xml 90 91 89 90 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 103 104 101 102 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
Reaction mixtures (16 mul) contained 25 mM MOPS, pH 7.2, 10 mM DTT, 31 mM NaCl, 10 mM MgCl2, 5 muM ZnSO4, 5 nM DNA substrate, and 0.49 muM IN. Reactions stopped by addition of an equal volume of sequencing gel sample buffer (95% formamide, 10 mM EDTA, 0.003% xylene cyanol, 0.003% bromophenol blue) were boiled for 2 min prior to fractionation through 20% polyacrylamide- (3' processing) or 15% polyacrylamide-8.3 M urea (DNA strand transfer) sequencing gels. Reaction products in wet gels exposed to phosphor image plates were quantified using Image Quant version 1.2 (GE Healthcare).
###end p 23
###begin p 24
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 375 376 372 373 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 401 402 397 398 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 305 310 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
LEDGFp75-dependent concerted integration activity was assayed essentially as previously described [31]. A preprocessed 32 bp U5 end was prepared by annealing AE3653 (5'-CCTTTTAGTCAGTGTGGAAAATCTCTAGCA) with AE3652 (5'- ACTGCTAGAGATTTTCCACACTGACTAAAAGG). Reactions (36 mul) were initiated by mixing 0.5 muM HIV-1 DNA with 0.33 mug pGEM-3 target DNA in 25.3 mM NaCl, 5.5 mM MgSO4, 11 mM DTT, 4.4 muM ZnCl2, 22 mM HEPES-NaOH, pH 7.4. IN (2 mul) in dilution buffer (750 mM NaCl, 10 mM DTT, 25 mM Tris-HCl, pH 7.4) was then added. Following 2-3 min at room temperature, 2.0 mul of LEDGFp75 was added, and the reactions were allowed to proceed at 37degreesC for 1 h. The final concentrations of IN and LEDGFp75 were both 0.8 muM. Reactions stopped by the addition of EDTA and SDS to the final concentrations of 25 mM and 0.5%, respectively, were deproteinized using 30 mug proteinase K (Roche Molecular Biochemicals, Indianapolis, IN) for 60 min at 37degreesC. DNAs recovered following precipitation with ethanol were separated on 1.5% agarose-TAE (40 mM Tris base, 20 mM acetate, 1 mM EDTA) gels run in TAE at 150 V for 2 h. DNAs stained with ethidium bromide (0.5 mug/ml) were quantified using Alpha Innotech FlourChem FC2.
###end p 24
###begin title 25
Cells and viruses
###end title 25
###begin p 26
###xml 189 190 189 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 358 360 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 643 645 640 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 727 729 724 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g </italic>
###xml 830 831 820 821 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 834 835 824 825 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 845 846 835 836 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 848 849 838 839 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 953 955 943 945 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g </italic>
###xml 101 107 <span type="species:ncbi:9913">bovine</span>
293T cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented to contain 10% fetal bovine serum (FBS) (Invitrogen Corporation, Carlsbad, CA). Cells were plated at 8.6 x 106/10-cm dish 24 h prior to transfection. Virus stocks were prepared by co-transfecting cells with 10 mug pNLX.Luc(R-) and 1 mug of envelope expression vector pCG-VSV-G [47] using FuGene 6 as described by the manufacturer (Roche Molecular Biochemicals). Cell-free supernatants harvested at 48 h post-transfection were passed through 0.45 mum filters. Virus titer was determined using an exogenous reverse transcriptase (RT) assay as previously described [48]. For western blot analysis, viruses pelletted by ultracentrifugation at 122,000 g for 2 h at 4degreesC were lysed for 15 min on ice in 40 mul of buffer containing 140 mM NaCl, 8 mM Na2HPO4, 2 mM NaH2PO4, 1% Nonidet P40, 0.5% Na deoxycholate, 0.05% SDS. Supernatant recovered after centrifugation at 19,800 g was stored at -80degreesC. Following electrophoresis and transfer to polyvinylidene fluoride, IN and p24 were detected using 1:100 and 1:5000 dilutions of 8G4 and 13-203-000 (Advanced Biotechnologies Inc, Columbia, MD) antibodies, respectively.
###end p 26
###begin p 27
###xml 15 17 15 17 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 263 265 262 264 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 698 700 695 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 836 838 833 835 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7 </sup>
###xml 869 871 866 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
HeLa-T4 cells [49] were grown in DMEM-10% FBS containing 100 IU/ml penicillin and 100 mug/ml streptomycin. For infectivity measurements, cells plated at 75,000 cells/well of 24-well tissue culture plates 24 h prior to infection were incubated in duplicate with 106 RT-cpm of virus for 17 h, after which cells washed with phosphate-buffered saline were replenished with fresh media. At 46 h post-infection, cells were collected, washed, and lysed using 75 mul passive lysis buffer as recommended by the manufacturer (Promega Corp., Madison, WI). Luciferase activities (20 mul), determined in duplicate for each infection, were normalized to total levels of cellular protein as previously described [42]. For quantitative (Q)-PCR assays, 900,000 cells were plated per 10 cm dish the day before infection. Cells were infected with 2.3 x 107 RT-cpm of TURBO DNase-treated [42] native or heat-inactivated (65degreesC for 30 min) virus. 8G4 hybridoma cells were grown in DMEM containing 10% ultra low IgG FBS (Invitrogen Corporation) with penicillin and streptomycin.
###end p 27
###begin title 28
Q-PCR assays for reverse transcription and integration
###end title 28
###begin p 29
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 541 543 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 796 798 795 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 420 425 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 501 513 <span type="species:ncbi:10710">phage lambda</span>
Total cellular DNA was isolated at 7 or 24 h post-infection using the QIAamp DNA mini kit (QIAGEN). Late reverse transcription (LRT) products were detected using primers and Taqman probe as previously described [50,51]. Two-long terminal repeat (2-LTR) containing circles were detected at 24 h post-infection using primers MH535/536 [50] and SYBR green (QIAGEN). Integration was measured at 24 h using a modified nested HIV-1 R-Alu format based on reference [52]. DNA (100 ng) was amplified using the phage lambda T-R chimera primer AE3014 [53] and Alu-specific AE1066 (5'-TCCCAGCTACTCGGGAGGCTGAGG) with rTth DNA polymerase XL as recommended by the manufacturer (Applied Biosystems Inc, Foster City, CA). Samples (1 mul) were then analyzed by Q-PCR using SYBR green with primers AE989 and AE990 [51]. DNA generated from WT-infected cells was end-point diluted in DNA prepared from uninfected cells to generate the integration standard curve. LRT, 2-LTR, and Alu-integration Q-PCR values obtained from samples prepared using heat-inactivated virus were subtracted from those generated using native virus.
###end p 29
###begin title 30
Results and Discussion
###end title 30
###begin title 31
Experimental strategy
###end title 31
###begin p 32
###xml 85 86 85 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 165 169 165 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vif </italic>
###xml 367 368 367 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 658 660 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 710 712 710 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 722 723 722 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 816 818 816 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1061 1062 1058 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1065 1067 1062 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1068 1070 1065 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1113 1115 1110 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 1175 1176 1172 1173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1365 1369 1362 1366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vif </italic>
###xml 1460 1464 1457 1461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vif </italic>
###xml 1645 1647 1642 1644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 34 39 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 225 230 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 801 806 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1142 1147 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 1212 1217 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Little is known about the role of HIV-1 IN C-terminal tail (residues 271-288, Figure 1) in integration. This region of the protein, which overlaps the 5' end of the vif reading frame, is fairly well conserved among different HIV-1 isolates. Some clade C sequences harbor Ala in place of Asp-278 and numerous clades as well as SIVcpz carry Gly at position 283 (Figure 1); the remaining residues by contrast show little or no sequence variation [54]. To ascertain the role of the tail in IN function, six nested deletions mutants lacking 3, 6, 9, 12, 15, or 18 amino acids from the C-terminus were constructed in the pKBIN6Hthr bacterial expression construct [39] and luciferase-based pNLX.Luc(R-) viral vector [42] (Figure 1). The CCD F185K mutation, which dramatically increases the solubility of the HIV-1 protein [38], was tested in some constructs to assess its potential affects on IN activities in vitro. The 1-266 deletion mutant, which lacked the C-terminal 22 residues and hence the fifth beta strand of the CTD SH3 fold in addition to the tail (Figure 1) [35,36], was used as a loss-of-function control [55]. Finally, the 23 residue HIV-2 tail (underlined in Figure 1) was swapped for the corresponding HIV-1 sequence to test the functionality of this marginally related sequence substitution. Because the viral changes necessarily altered the overlapping vif sequence, these constructs incorporated stop codons downstream of the IN region within the vif frame to negate synthesis of altered Vif proteins. Viruses were constructed in 293T cells, which lack APOBEC3G and thus do not require functional Vif to yield infectious particles [56].
###end p 32
###begin p 33
###xml 0 62 0 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink">IN sequence alignment and HIV-1 mutants analyzed in this study</bold>
###xml 544 546 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 547 549 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 26 31 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 245 250 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 333 338 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 698 703 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 728 733 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
IN sequence alignment and HIV-1 mutants analyzed in this study. The upper drawing indicates the three IN domains, with amino acid residues conserved among all retroviruses noted. CTD sequences downstream of the invariant Trp are shown below for HIV-1 (NL4-3 isolate, accession number M19921), SIVcpz (accession number AF115393), and HIV-2 (ROD isolate, accession number M15390). Residues that appear in more than one sequence are highlighted in grey. The broad arrows beneath the alignment indicate the beta strands that comprise the SH3 fold [35,36]. Numbers 266-285 above the alignment mark the IN deletion mutant enzymes and viruses analyzed in this study. The underline indicates the region of HIV-2 IN that was swapped for HIV-1 residues 271-288.
###end p 33
###begin title 34
The C-terminal tail and IN enzymatic activities
###end title 34
###begin p 35
###xml 316 324 316 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 794 796 794 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 316 323 <span type="species:ncbi:562">E. coli</span>
Recombinant proteins were engineered to contain C-terminal hexahistidine tags to facilitate purification. Though this might appear counterintuitive given the C-terminal focus of the study, it was necessary to obtain relatively pure preparations. The tail region is hypersensitive to proteolysis during expression in E. coli [57], and preliminary experiments with N-terminally tagged proteins yielded heterogeneous populations eluted from Ni-NTA beads whose purities were not substantially improved upon by subsequent ion exchange or size exclusion chromatography (data not shown). The C-terminal tag obviated this problem, as proteolyzed variants failed to bind Ni-NTA beads. Indeed, quantitative image analysis of purified WT and mutant proteins revealed near homogeneous preparations (Figure 2A).
###end p 35
###begin p 36
###xml 0 50 0 50 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Integrase proteins and in vitro integration assays</bold>
###xml 569 572 568 571 <sub xmlns:xlink="http://www.w3.org/1999/xlink">OH </sub>
###xml 1359 1361 1358 1360 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
Integrase proteins and in vitro integration assays. (A) Purified proteins (approximately 5 mug each) were stained with Coomassie blue following SDS-polyacrylamide gel electrophoresis. Migration positions of molecular mass standards in kDa are shown on the left. (B) 3' Processing assay. The blunt-ended viral DNA substrate is shown highlighting the subterminal CA that is conserved among all retroviruses, retrotransposons, and some bacterial transposases. During 3' processing, IN cleaves the A/G phosphodiester bond (short vertical arrow), releasing radiolabelled pGTOH dinucleotide. (C) The DNA strand transfer assay utilizes a preprocessed viral DNA end. Integration into target DNA yields products whose lengths exceed that of the starting substrate. (D) Two different DNAs, viral donor (oligonucleotide drawn in the same orientation as in panel C, top) and circular target, are used in the concerted integration assay. In the presence of LEDGFp75, some donor DNA is integrated into only one strand of the target to yield a tagged, nicked circle half-site reaction product. Concerted integration across the major groove by contrast yields a linearized product whose length exceeds that of the starting circle by twice the length of the viral donor. For panels B-D, thin and bold lines represent viral donor and target DNAs, respectively. *, positions of 32P label (panels B and C).
###end p 36
###begin p 37
###xml 140 144 140 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B-D</xref>
###xml 310 312 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 507 508 507 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 720 722 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 763 765 763 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 860 862 860 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 967 969 967 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2D</xref>
###xml 1045 1046 1045 1046 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 892 897 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1285 1290 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
IN activities were measured using three different assay designs, each of which incorporated an ~30 bp DNA mimic of the viral U5 end (Figure 2B-D). Overall levels of IN 3' processing and DNA strand transfer activities were determined in two separate assays using differentially labeled 30 bp substrates (Figure 2B and 2C). Under these conditions, the majority of DNA strand transfer reaction products result from the insertion of a single oligonucleotide end into one strand of a second target DNA molecule [8]. By contrast, integration in cells proceeds via the concerted insertion of viral U3 and U5 DNA ends into opposing strands of chromosomal DNA. Reactions that contain relatively low concentrations of IN protein [58], relatively long viral DNA substrates [59], or relatively high concentrations of oligonucleotide substrate in the presence of LEDGFp75 [31] support efficient concerted HIV-1 integration. Here, LEDGFp75 was used in a third assay format (Figure 2D) to monitor the concerted integration activities of IN mutant proteins. His6-tags were removed from purified IN proteins by thrombin cleavage prior to enzyme assays, yielding the remnant LVPR C-terminal sequence. Experiments conducted with a subset of proteins prior to cleavage (WT, 1-279, 1-273, 1-270,1-266, and HIV-1/2) revealed similar levels of 3' processing activities relative to WT, indicating that the remnant sequence did not significantly influence mutant enzyme activities (data not shown).
###end p 37
###begin p 38
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 197 199 197 199 <sub xmlns:xlink="http://www.w3.org/1999/xlink">OH</sub>
###xml 323 324 323 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 325 326 325 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 450 453 450 453 <sub xmlns:xlink="http://www.w3.org/1999/xlink">OH </sub>
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 568 570 568 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 638 640 638 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 645 650 645 650 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D64N </sub>
###xml 656 661 656 661 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-266</sub>
###xml 735 737 735 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 824 826 824 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 916 921 916 921 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-285</sub>
###xml 925 930 925 930 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-282</sub>
###xml 938 943 938 943 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-279</sub>
###xml 990 992 990 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 1115 1120 1115 1120 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-276</sub>
###xml 1124 1129 1124 1129 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-273</sub>
###xml 1137 1143 1137 1143 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-270 </sub>
###xml 1216 1222 1216 1222 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-279 </sub>
###xml 1228 1234 1228 1234 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-270 </sub>
###xml 1244 1246 1244 1246 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1343 1346 1343 1346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 1347 1349 1347 1349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1358 1365 1358 1365 <sub xmlns:xlink="http://www.w3.org/1999/xlink">HIV1/2 </sub>
###xml 1388 1394 1388 1394 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-270 </sub>
###xml 1447 1449 1447 1449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 1467 1469 1467 1469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 1634 1636 1634 1636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
To follow the course of the 3' processing reaction, oligonucleotide substrate DNA was labeled at the inter-nucleotide linkage of the 3'-terminal GT (Figure 2B); IN mediated hydrolysis liberates pGTOH, which is readily distinguished from the 30 bp substrate following electrophoresis on high percentage DNA sequencing gels [3,4] (Figure 3A, lanes 2 and 3; results quantified in panel B). Exonuclease III-mediated hydrolysis by contrast yielded free pTOH (Figure 3A, lanes 1 and 17). All IN preparations were basically void of contaminating exonuclease activity (Figure 3A), reflecting the relatively high degrees of protein purity (Figure 2A). IND64N and IN1-266, which contained the substitution of Asn for active site residue Asp-64 [14] and lacked part of the CTD SH3 fold, respectively, were predictably inactive (Figure 3A, lanes 15 and 16). The activities of the three mutants that retained most of the tail, IN1-285, IN1-282, and IN1-279, were overall similar at 65-70% of WT (Figure 3A, lanes 5-7). Mutants with further progressive tail deletions yielded a stepwise reduction in 3' processing activity, as IN1-276, IN1-273, and IN1-270 supported about 51%, 26%, and 13%, respectively, of WT function. Thus, IN1-279 and IN1-270 support Mg2+-dependent 3' processing activities that do not significantly differ from those reported using Mn2+ [25]. The INHIV1/2 chimera protein like IN1-270 retained marginal (about 12% of WT) activity (Figure 3A, lane 20; Figure 3B). The F185K solubility mutation marginally impacted activity, generally yielding 20-25% reductions when compared to the same protein lacking the CCD change (Figure 3B).
###end p 38
###begin p 39
###xml 0 41 0 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink">WT and mutant IN 3' processing activities</bold>
###xml 152 155 152 155 <sub xmlns:xlink="http://www.w3.org/1999/xlink">OH </sub>
###xml 182 185 182 185 <sub xmlns:xlink="http://www.w3.org/1999/xlink">OH </sub>
###xml 502 507 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
WT and mutant IN 3' processing activities. (A) Polyacrylamide gel images reveal the migration positions of labeled 30-mer DNA substrate (S), cleaved pGTOH dinucleotide, as well as pTOH mononucleotide. The reactions loaded in lanes 1 and 17 contained exonuclease III in place of IN, whereas lanes 2 and 18 omitted IN. The reactions in the remaining lanes contained the indicated IN proteins. (B) Mutant 3' processing activities plotted as percentage of WT IN function. Results are mean +/- SEM for two (HIV-1/2 chimera) to four (all other mutants) independent experiments.
###end p 39
###begin p 40
###xml 243 244 243 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 425 427 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 445 450 445 450 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-285</sub>
###xml 454 459 454 459 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-279</sub>
###xml 467 473 467 473 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-276 </sub>
###xml 568 574 568 574 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-270 </sub>
###xml 599 601 599 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 628 630 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 635 637 635 637 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 680 683 680 683 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 684 685 684 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 686 688 686 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 765 771 765 771 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-270 </sub>
###xml 801 803 801 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 808 815 808 815 <sub xmlns:xlink="http://www.w3.org/1999/xlink">HIV1/2 </sub>
###xml 862 867 862 867 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-270</sub>
###xml 941 943 941 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 948 950 948 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
The preprocessed DNA strand transfer substrate was labeled at the 5' end of the strand that becomes joined to target DNA; IN activity yields a population of products that migrate more slowly than the starting substrate on DNA sequencing gels [8] (Figure 2C and 4A). Relative levels of IN mutant DNA strand transfer activities in large part mirrored 3' processing activities with some subtle differences noted (compare Figure 4B to Figure 3B). IN1-285, IN1-279, and IN1-276 supported DNA strand transfer at basically the same level as the WT, whereas the activity of IN1-270 was undetectable (Figure 4A, lanes 4-6 and 13; Figure 4B). Mn2+can support more robust IN activity than Mg2+ [9,60], which may have contributed to the previously reported residual level of IN1-270 DNA strand transfer activity [25]. INHIV1/2 DNA strand transfer activity, by contrast to IN1-270, was increased from its relative level of 3' processing activity (Figure 4B and 3B).
###end p 40
###begin p 41
###xml 0 40 0 40 <bold xmlns:xlink="http://www.w3.org/1999/xlink">IN mutant DNA strand transfer activities</bold>
IN mutant DNA strand transfer activities. (A) Scanned gel images show the migration positions of preprocessed substrate (S) DNA as well as the integration products (IP) of DNA strand transfer. IN was omitted from the reactions loaded in lanes 1 and 16; the remaining lanes contained the indicated IN proteins. (B) Mean DNA strand transfer activities +/- SEM for two independent experiments plotted as percentage of WT IN activity.
###end p 41
###begin p 42
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2D</xref>
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2D</xref>
###xml 648 650 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 709 711 709 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 888 890 888 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 1012 1014 1012 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 1088 1090 1088 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C</xref>
###xml 1283 1290 1282 1289 <sub xmlns:xlink="http://www.w3.org/1999/xlink">HIV1/2 </sub>
###xml 1315 1318 1314 1317 <sub xmlns:xlink="http://www.w3.org/1999/xlink">WT </sub>
###xml 1370 1372 1369 1371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 1477 1479 1475 1477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 1522 1529 1520 1527 <sub xmlns:xlink="http://www.w3.org/1999/xlink">HIV1/2 </sub>
###xml 1604 1606 1601 1603 <sub xmlns:xlink="http://www.w3.org/1999/xlink">WT</sub>
###xml 1615 1617 1612 1614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 1638 1640 1635 1637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 1710 1712 1707 1709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C</xref>
###xml 2017 2019 2014 2016 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 2114 2116 2111 2113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 2262 2264 2259 2261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 2409 2411 2406 2408 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 2478 2479 2475 2476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 2481 2482 2478 2479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 2484 2485 2481 2482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 2622 2628 2619 2625 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-279 </sub>
###xml 2634 2640 2631 2637 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-276 </sub>
###xml 2752 2757 2749 2754 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-270</sub>
###xml 2855 2856 2852 2853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 2861 2862 2858 2859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 1888 1893 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2352 2357 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Supercoiled pGEM-3 plasmid DNA was incorporated into the reaction mixture to help identify concerted integration reaction products (Figure 2D and 5A). Integration of only one donor DNA end into one plasmid DNA strand yields a tagged circle whose mobility through agarose matches that of starting relaxed circular plasmid (Figure 5A). Pairwise integration of two oligonucleotides by contrast yields a linearized product whose size is slightly larger than linear plasmid (Figure 2D). IN DNA strand transfer activity was barely detectable in the absence of LEDGFp75, yielding slight increases in the nicked or open circular plasmid population (Figure 5A, compare lanes 3 and 27 to lanes 2 and 26, respectively) [31]. LEDGFp75 greatly stimulated IN activity such that the supercoiled target DNA was largely consumed, yielding a mixture of half-site and concerted integration products (Figure 5A, lanes 4 and 28). IN mutant product formation was quantified to reflect overall levels (half-site plus concerted, Figure 5B) of DNA strand transfer activities or just concerted integration (Figure 5C). The overall activities of the various deletion mutant proteins in large part mirrored their oligonucleotide-based DNA strand transfer activities (compare Figure 5B to 4B). Though 0.49 muM INHIV1/2 supported about 40% of INWT activity in the oligonucleotide-based assay (Figure 4B), 0.8 muM protein failed to support appreciable product formation in the concerted assay format (Figure 5A, lane 31). Doubling the amount of input INHIV1/2 to 1.6 muM yielded significant half-site product formation (about 66% of INWT, Figure 5A, lane 30 and Figure 5B) in the absence of detectable concerted integration activity (Figure 5C). Taken together, our data indicate that the C-terminal tail does not play a specific role in concerted DNA integration, though the introduction of a foreign sequence for the HIV-1 tail can uncouple pairwise from single end integration activity. Though others noted that the F185K substitution ablated Mg2+-dependent integration of preprocessed oligonucleotide donor DNA into heterologous target DNA [61], our reaction conditions failed to reveal an affect of the solubilizing mutation on full-length IN activity in the presence of LEDGFp75 (Figure 5A, lane 6; panels B and C). We furthermore conclude that the C-terminal 9 amino acids of HIV-1 IN can be removed without dramatically effecting Mg2+-based single end or concerted DNA integration activities (Figures 3, 4, 5)., We highlight these derivatives as potential candidates for structural biology studies despite the approximate 20-25% reductions in IN1-279 and IN1-276 activities brought on by the F185K change. We would by contrast advise against extensive analysis of tailless IN1-270, due to its lack of detectable DNA strand transfer activity under these assay conditions (Figure 4 and 5).
###end p 42
###begin p 43
###xml 0 80 0 80 <bold xmlns:xlink="http://www.w3.org/1999/xlink">LEDGFp75-dependent concerted integration activities of WT and IN mutant proteins</bold>
###xml 800 803 798 801 <sub xmlns:xlink="http://www.w3.org/1999/xlink">WT </sub>
###xml 511 516 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
LEDGFp75-dependent concerted integration activities of WT and IN mutant proteins. (A) The scanned ethidium-stained agarose gels reveal the migration positions of donor, supercoiled (s.c.), and open circular (o.c.) substrate DNAs, as well as half-site and concerted integration reaction products. Donor DNA was omitted from the reactions analyzed in lanes 1 and 25, whereas IN was omitted from lanes 2 and 26. The remaining lanes contained the indicated IN proteins and, at times, LEDGFp75. The concentration of HIV-1/2 IN in lanes 29 and 30 was 1.6 muM, whereas all other IN concentrations were 0.8 muM. The migration positions of molecular mass standards in kb are shown to the left of the gel. (B and C) Levels of overall and concerted DNA strand transfer activities, respectively, normalized to INWT (set to 100%). Results are mean +/- SEM for two independent experiments.
###end p 43
###begin title 44
Characterization of IN mutant viruses
###end title 44
###begin p 45
###xml 156 159 156 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nef</italic>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 428 429 428 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 448 454 448 454 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-276 </sub>
###xml 463 469 463 469 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-273 </sub>
###xml 554 559 554 559 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-270</sub>
###xml 566 571 566 571 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-266</sub>
###xml 630 631 630 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 10 15 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 402 407 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 443 446 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 458 461 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 549 552 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 561 564 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 581 586 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To assess HIV-1 infectivity, HeLa-T4 cells were infected with normalized levels of single-round viruses that carry the luciferase reporter gene in place of nef. Two days post-infection, cells were harvested and resulting luciferase activities were normalized to the levels of total protein in the different cell extracts [42,47]. Deletion of up to 9 amino acids from the IN C-terminus failed to affect HIV-1 infectivity (Figure 6). IN mutants HIV-11-276 and HIV-11-273 supported about 50% and 20% of the level of WT infection, respectively, whereas HIV-11-270, HIV-11-266, and the HIV-1/2 tail chimera were non-infectious (Figure 6).
###end p 45
###begin p 46
###xml 0 27 0 27 <bold xmlns:xlink="http://www.w3.org/1999/xlink">IN mutant viral infectivity</bold>
###xml 99 104 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
IN mutant viral infectivity. Normalized levels of IN mutant infectivities are shown relative to WT HIV-1 (set at 100%). Each experiment amassed duplicate luciferase assays of duplicate infections. Shown is the mean +/- SEM of five independent experiments. RLU, relative light units.
###end p 46
###begin p 47
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 697 702 697 702 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-266</sub>
###xml 709 714 709 714 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-270</sub>
###xml 721 726 721 726 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-273</sub>
###xml 733 738 733 738 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-276</sub>
###xml 760 761 760 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 971 973 971 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 1140 1141 1140 1141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 1233 1238 1233 1238 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-276</sub>
###xml 1245 1250 1245 1250 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-273</sub>
###xml 1257 1262 1257 1262 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-270</sub>
###xml 1273 1279 1273 1279 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-266 </sub>
###xml 1392 1398 1392 1398 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-266 </sub>
###xml 46 51 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 692 695 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 704 707 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 716 719 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 728 731 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 744 749 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1228 1231 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1240 1243 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1252 1255 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1268 1271 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1324 1329 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1387 1390 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
IN mutations can affect multiple steps in the HIV-1 replication cycle, including particle release from virus-producing cells and/or reverse transcription during the subsequent round of infection (reviewed in ref. [62]). Viruses specifically blocked at integration are distinguished as class I, whereas class II mutants display additional stage defects. To assess potential affects on virus particle release, RT content in HeLa cell supernatants at 2 days post-transfection was normalized to levels of cell-associated luciferase activity. Normalized levels of mutant virus release did not significantly differ from the WT under this assay condition (data not shown). Defective mutant viruses (HIV-11-266, HIV-11-270, HIV-11-273, HIV-11-276, and HIV-1/2; Figure 6) produced from transfected 293T cells were analyzed by western blotting to assess levels of virion-incorporated IN protein. Monoclonal antibody 8G4, which recognizes discontinuous epitopes in the NTD and CCD [45], was utilized to avoid potential complications from the CTD mutations. Accordingly, 8G4 effectively recognized the different forms of recombinant IN protein (Figure 7, top panel). Based on relative levels of p24 content (bottom panel), we conclude that HIV-11-276, HIV-11-273, HIV-11-270, and HIV-11-266 harbor significantly less IN protein than WT HIV-1 (viral lysate panels, compare lanes 2-5 to lane 1), with HIV-11-266 suffering the most dramatic defect (lane 2). We therefore conclude that an intact SH3 fold plays an important role in Gag-Pol incorporation and/or IN retention in virions.
###end p 47
###begin p 48
###xml 0 38 0 38 <bold xmlns:xlink="http://www.w3.org/1999/xlink">WT and IN mutant virus protein content</bold>
WT and IN mutant virus protein content. Top panel, 2 ng of the indicated recombinant IN protein was analyzed by western blotting. Lower panels, viral lysates. The primary blotting antibody is indicated to the right of each panel.
###end p 48
###begin p 49
###xml 551 557 551 557 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-276 </sub>
###xml 566 572 566 572 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-273 </sub>
###xml 650 652 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8A</xref>
###xml 657 659 657 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8B</xref>
###xml 675 680 675 680 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-270</sub>
###xml 687 692 687 692 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-266</sub>
###xml 787 789 787 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8A</xref>
###xml 1049 1051 1049 1051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 1080 1082 1080 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 1083 1085 1083 1085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 1169 1171 1166 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 1221 1222 1215 1216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1411 1413 1405 1407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 546 549 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 561 564 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 670 673 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 682 685 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 702 707 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 918 923 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Q-PCR assays were utilized to assess defective mutant virus reverse transcription (LRT at 7 h post-infection) and 2-LTR circle formation and integration (nested Alu-R PCR) at 24 h. Virus stocks were treated with DNase prior to infection to digest plasmid DNA that may persist after transfection and hence template in the LRT reaction format. To control for potential plasmid carry-over, a parallel set of infections was conducted using heat-inactivated viruses. Resulting LRT values (typically 1-5%) were subtracted from native viral infections. HIV-11-276 and HIV-11-273 supported the WT levels of reverse transcription and circle formation (Figure 8A and 8B), whereas HIV-11-270, HIV-11-266, and the HIV-1/2 chimera supported about 25%, 5%, and 33% of WT LRT product formation (Figure 8A). Under these experimental conditions IN residues 271-273 contribute to reverse transcription. Due to the pleiotropic nature of HIV-1 IN mutations these results were not entirely unexpected. Residues 271-273 might influence the interaction between IN and RT [63], which occurs via the CTD [64,65]. An RT binding interface was recently mapped to beta strands 2-4 of the SH3 fold [66] and though residues 271-273 abut beta-5 (Figure 1), it is not unreasonable to suspect the disordered tail could affect RT binding. Alternatively, a number of NTD and CCD mutations in addition to CTD changes can impair DNA synthesis (see [62] for review), indicating that the C-terminal tail changes might perturb reverse transcription via global affects on IN and/or the preintegration complex.
###end p 49
###begin p 50
###xml 0 67 0 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Reverse transcription and integration profiles of IN mutant viruses</bold>
Reverse transcription and integration profiles of IN mutant viruses. (A) Mutant viral LRT levels, graphed as percentages of the WT (leftward bar). (B) 2-LTR circle levels at 24 h post-infection. (C) Mutant viral integration in comparison to the WT. Panels A and B average results of two different infection experiments (mean +/- SEM). Mean +/- SEM of duplicate Q-PCR assays of one infection experiment is shown in panel C. The panel C data are representative of those obtained from a duplicate set of infections.
###end p 50
###begin p 51
###xml 5 11 5 11 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-276 </sub>
###xml 20 26 20 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-273 </sub>
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8C</xref>
###xml 151 152 151 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 275 276 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 278 279 278 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 281 282 281 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 434 440 434 440 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-270 </sub>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8C</xref>
###xml 623 625 623 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8B</xref>
###xml 786 792 786 792 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-266 </sub>
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 15 18 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 429 432 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 448 453 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 781 784 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV-11-276 and HIV-11-273 supported about 40% and 20% of WT integration, respectively (Figure 8C), indicating that their partial infectivities (Figure 6) were due to specific integration defects attributable to the intrinsic activities of the deletion mutant enzymes (Figure 3, 4, 5). Consistent with their non-infectious phenotypes and inabilities for recombinant IN proteins to catalyze concerted integration activity, neither HIV-11-270 nor the HIV-1/2 chimera supported a detectable level of integration during infection (Figure 8C). As both of these viruses supported the formation of detectable 2-LTR circles (Figure 8B), we group them as class II defective IN mutants that display marginal (3 to 4-fold) reverse transcription in additional to prominent integration defects. HIV-11-266 was a more severe class II mutant virus, harboring a significant reverse transcription as well as integration defect.
###end p 51
###begin title 52
Conclusion
###end title 52
###begin p 53
###xml 388 394 388 394 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-276 </sub>
###xml 400 406 400 406 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-273 </sub>
###xml 432 434 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 663 669 663 669 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-270 </sub>
###xml 851 856 851 856 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-266</sub>
###xml 81 86 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 658 661 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 846 849 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The results of this study revealed that nine amino acids can be removed from the HIV-1 IN C-terminus without significantly affecting the activity of the enzyme or infectivity of the virus. Additional removal of up to six amino acids impacted infectivity by up to 80%, yielding viruses that were specifically defective for integration due to the compromised activities of the associated IN1-276 and IN1-273 enzymes. Heuer and Brown [67] reported that residues 271-288 crosslink to viral and target DNA sequences within junctional disintegration substrates. We would therefore surmise that tail residues 271-279 interact with substrate DNA during integration. HIV-11-270 was non-infectious and harbored an approximate fourfold reverse transcription defect. This suggests IN residues 271, 272, and 273 might impact its physical association with RT. HIV-11-266, which lacked the fifth beta strand of the fold, failed to incorporate significant levels of IN protein and was in large part defective for reverse transcription. Thus, an intact SH3 fold apparently contributes to Gag-Pol packaging and subsequent viral DNA synthesis. Our results moreover highlight partial tailed variants 1-279/F185K and 1-276/F185K as viable candidates for structural biology studies, as they retained >20% of IN enzymatic activities yet lacked at least half of the disordered region.
###end p 53
###begin title 54
List of abbreviations used
###end title 54
###begin p 55
###xml 301 303 301 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 202 208 <span type="species:ncbi:9913">bovine</span>
CCD: catalytic core domain; CHAPS: 3-[(3-Cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonate; CTD: C-terminal domain; DMEM: Dulbecco's modified Eagle's medium; DTT: dithiothreitol; FBS: fetal bovine serum; IN: integrase; LRT: late reverse transcription; LTR: long-terminal repeat; Ni-NTA: Ni2+-nitrilotriacetic acid; NTD: N-terminal domain; Q: quantitative; RT: reverse transcriptase; SDS: Na dodecyl sulfate; WT: wild type.
###end p 55
###begin title 56
Competing interests
###end title 56
###begin p 57
The authors declare that they have no competing interests.
###end p 57
###begin title 58
Authors' contributions
###end title 58
###begin p 59
MJD constructed molecular clones, purified recombinant IN proteins, and conducted in vitro integration assays. BM performed the brunt of virological measurements including infectivity, LRT, and 2-LTR circle Q-PCRs. LK purified 8G4 antibody, performed western blotting, and performed some IN purifications and enzyme assays. MCS performed Alu-PCR and quantified virus release from transfected HeLa cells. FDN devised the western blotting procedure, and trained and supervised BM. DEH supplied essential reagents. AE conceived of the study, supervised and interpreted experimental results, and wrote the manuscript. All authors read and approved the final manuscript.
###end p 59
###begin title 60
Acknowledgements
###end title 60
###begin p 61
###xml 433 438 <span type="species:ncbi:9606">Human</span>
The authors thank Nan Yan for valuable technical advice. This work was supported by US NIH grants AI039394 and AI070042 (to AE) and the Harvard University Center for AIDS Research (CFAR), an NIH funded program (P30AI060354) that is supported by the following NIH Institutes and Centers: NIAID, NCI, NIMH, NIDA, NICHD, NHLBI, NCCAM. The contents of this manuscript do not necessarily reflect the views of the Department of Health and Human Services, nor does the mention of trade names, commercial products, or organizations imply endorsement by the US Government.
###end p 61
###begin article-title 62
###xml 23 26 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Molecular mechanism of HIV integration and therapeutic intervention
###end article-title 62
###begin article-title 63
###xml 42 47 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Two bases are deleted from the termini of HIV-1 linear DNA during integrative recombination
###end article-title 63
###begin article-title 64
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer
###end article-title 64
###begin article-title 65
###xml 44 72 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Site-specific hydrolysis and alcoholysis of human immunodeficiency virus DNA termini mediated by the viral integrase protein
###end article-title 65
###begin article-title 66
###xml 27 32 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Modeling the late steps in HIV-1 retroviral integrase-catalyzed DNA integration
###end article-title 66
###begin article-title 67
Repair of gaps in retroviral DNA integration intermediates
###end article-title 67
###begin article-title 68
###xml 0 28 <span type="species:ncbi:12721">Human immunodeficiency virus</span>
###xml 62 78 <span type="species:ncbi:562">Escherichia coli</span>
Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity
###end article-title 68
###begin article-title 69
###xml 14 42 <span type="species:ncbi:12721">human immunodeficiency virus</span>
###xml 44 47 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 116 119 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Activities of human immunodeficiency virus (HIV) integration protein in vitro: Specific cleavage and integration of HIV DNA
###end article-title 69
###begin article-title 70
###xml 30 65 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Efficient magnesium-dependent human immunodeficiency virus type 1 integrase activity
###end article-title 70
###begin article-title 71
###xml 53 58 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Integrase and integration: biochemical activities of HIV-1 integrase
###end article-title 71
###begin article-title 72
###xml 36 41 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity
###end article-title 72
###begin article-title 73
###xml 38 66 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Zn2+ promotes the self-association of human immunodeficiency virus type-1 integrase in vitro
###end article-title 73
###begin article-title 74
###xml 94 99 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Identification of amino acid residues critical for endonuclease and integration activities of HIV-1 IN protein in vitro
###end article-title 74
###begin article-title 75
###xml 61 96 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro
###end article-title 75
###begin article-title 76
Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases
###end article-title 76
###begin article-title 77
###xml 48 83 <span type="species:ncbi:11709">human immunodeficiency virus type 2</span>
Mutational analysis of the integrase protein of human immunodeficiency virus type 2
###end article-title 77
###begin article-title 78
###xml 64 69 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Biophysical and enzymatic properties of the catalytic domain of HIV-1 integrase
###end article-title 78
###begin article-title 79
###xml 19 24 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The core domain of HIV-1 integrase recognizes key features of its DNA substrates
###end article-title 79
###begin article-title 80
###xml 26 31 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Critical contacts between HIV-1 integrase and viral DNA identified by structure-based analysis and photo-crosslinking
###end article-title 80
###begin article-title 81
###xml 49 54 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction
###end article-title 81
###begin article-title 82
Role of the nonspecific DNA-binding region and alpha helices within the core domain of retroviral integrase in selecting target DNA sites for integration
###end article-title 82
###begin article-title 83
###xml 7 14 <span type="species:ncbi:9606">patient</span>
###xml 23 58 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Use of patient-derived human immunodeficiency virus type 1 integrases to identify a protein residue that affects target site selection
###end article-title 83
###begin article-title 84
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV integrase structure and function
###end article-title 84
###begin article-title 85
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 integrase: arrangement of protein domains in active cDNA complexes
###end article-title 85
###begin article-title 86
###xml 62 90 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Identification of the catalytic and DNA-binding region of the human immunodeficiency virus type I integrase protein
###end article-title 86
###begin article-title 87
###xml 62 67 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Characterization of a DNA binding domain in the C-terminus of HIV-1 integrase by deletion mutagenesis
###end article-title 87
###begin article-title 88
###xml 67 102 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The core and carboxyl-terminal domains of the integrase protein of human immunodeficiency virus type 1 each contribute to nonspecific DNA binding
###end article-title 88
###begin article-title 89
###xml 27 32 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A soluble active mutant of HIV-1 integrase: involvement of both the core and the C-terminal domains in multimerization
###end article-title 89
###begin article-title 90
###xml 38 43 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein
###end article-title 90
###begin article-title 91
Structural basis for functional tetramerization of lentiviral integrase
###end article-title 91
###begin article-title 92
A novel co-crystal structure affords the design of gain-of-function lentiviral integrase mutants in the presence of modified PSIP1/LEDGF/p75
###end article-title 92
###begin article-title 93
###xml 25 30 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: A model for viral DNA binding
###end article-title 93
###begin article-title 94
###xml 19 48 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
X-ray structure of simian immunodeficiency virus integrase containing the core and C-terminal domain (residues 50-293) - an initial glance of the viral DNA binding platform
###end article-title 94
###begin article-title 95
###xml 56 74 <span type="species:ncbi:11886">rous sarcoma virus</span>
Crystal structure of an active two-domain derivative of rous sarcoma virus integrase
###end article-title 95
###begin article-title 96
###xml 26 31 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The DNA-binding domain of HIV-1 integrase has an SH3-like fold
###end article-title 96
###begin article-title 97
###xml 48 53 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Solution structure of the DNA binding domain of HIV-1 integrase
###end article-title 97
###begin article-title 98
###xml 74 109 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Genetic analyses of conserved residues in the carboxyl terminal domain of human immunodeficiency virus type 1 integrase
###end article-title 98
###begin article-title 99
###xml 20 55 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Catalytic domain of human immunodeficiency virus type 1 integrase: Identification of a soluble mutant by systematic replacement of hydrophobic residues
###end article-title 99
###begin article-title 100
###xml 22 27 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Dynamic modulation of HIV-1 integrase structure and function by cellular lens epithelium-derived growth factor (LEDGF) protein
###end article-title 100
###begin article-title 101
###xml 24 59 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Nuclear localization of human immunodeficiency virus type 1 preintegration complexes (PICs): V165A and R166A are pleiotropic integrase mutants primarily defective for integration, not PIC nuclear import
###end article-title 101
###begin article-title 102
###xml 37 42 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In vivo biotinylation and capture of HIV-1 matrix and integrase proteins
###end article-title 102
###begin article-title 103
###xml 135 170 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Class II integrase mutants with changes in putative nuclear localization signals are primarily blocked at a post-nuclear entry step of human immunodeficiency virus type 1 replication
###end article-title 103
###begin article-title 104
LEDGF/p75 interacts with divergent lentiviral integrases and modulates their enzymatic activity in vitro
###end article-title 104
###begin article-title 105
###xml 216 221 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Biochemical and genetic analyses of integrase-interacting proteins lens epithelium-derived growth factor (LEDGF)/p75 and hepatoma-derived growth factor related protein 2 (HRP2) in preintegration complex function and HIV-1 replication
###end article-title 105
###begin article-title 106
###xml 30 65 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Monoclonal antibodies against human immunodeficiency virus type 1 integrase: epitope mapping and differential effects on integrase activities in vitro
###end article-title 106
###begin article-title 107
Integrase
###end article-title 107
###begin article-title 108
###xml 20 55 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Wild-type levels of human immunodeficiency virus type 1 infectivity in the absence of cellular emerin protein
###end article-title 108
###begin article-title 109
###xml 33 68 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication
###end article-title 109
###begin article-title 110
###xml 24 34 <span type="species:ncbi:11676">AIDS virus</span>
The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain
###end article-title 110
###begin article-title 111
###xml 25 28 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
A quantitative assay for HIV DNA integration in vivo
###end article-title 111
###begin article-title 112
###xml 93 98 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration
###end article-title 112
###begin article-title 113
###xml 18 53 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Analysis of early human immunodeficiency virus type 1 DNA synthesis by use of a new sensitive assay for quantifying integrated provirus
###end article-title 113
###begin article-title 114
###xml 25 30 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Quantitative analysis of HIV-1 preintegration complexes
###end article-title 114
###begin article-title 115
###xml 21 26 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors
###end article-title 115
###begin article-title 116
###xml 49 54 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex
###end article-title 116
###begin article-title 117
###xml 80 85 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif
###end article-title 117
###begin article-title 118
###xml 29 34 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Heterogeneity in recombinant HIV-1 integrase corrected by site-directed mutagenesis: the identification and elimination of a protease cleavage site
###end article-title 118
###begin article-title 119
###xml 12 47 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Recombinant human immunodeficiency virus type 1 integrase exhibits a capacity for full-site integration in vitro that is comparable to that of purified preintegration complexes from virus-infected cells
###end article-title 119
###begin article-title 120
###xml 42 47 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Processing of viral DNA ends channels the HIV-1 integration reaction to concerted integration
###end article-title 120
###begin article-title 121
###xml 30 35 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Metal-dependent inhibition of HIV-1 integrase by {beta}-diketo acids and resistance of the soluble double-mutant (F185K/C280S)
###end article-title 121
###begin article-title 122
###xml 9 14 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Modeling HIV-1 integrase complexes based on their hydrodynamic properties
###end article-title 122
###begin article-title 123
In vivo analysis of retroviral integrase structure and function
###end article-title 123
###begin article-title 124
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex
###end article-title 124
###begin article-title 125
###xml 20 55 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Interaction between human immunodeficiency virus type 1 reverse transcriptase and integrase proteins
###end article-title 125
###begin article-title 126
###xml 58 93 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase
###end article-title 126
###begin article-title 127
###xml 44 49 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Identifying and characterizing a functional HIV-1 reverse transcriptase-binding site on integrase
###end article-title 127
###begin article-title 128
###xml 20 25 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Mapping features of HIV-1 integrase near selected sites on viral and target DNA molecules in an active enzyme-DNA complex by photo-cross-linking
###end article-title 128

